


## **Press release January 2014**

### **Arterius Limited wins EU grant**

Arterius Limited has been awarded a research grant from the European Union (Seven Framework Programme, FP7) for a collaborative project to develop the next generation of biodegradable coronary stent for the treatment of coronary artery disease. The project started in January 2014 with fourteen members collaborating on the project and total costs of €5.8 million.



The incidence of coronary artery disease is increasing worldwide given the growing ageing population and increased risk factors such as diabetes, obesity and hypertension. Effective therapies are needed to ensure quality long-term results for patients. New stent technologies such as biodegradable stents, that provide the temporary support to the vessel and disappear overtime, are a viable alternative to the current permanent metallic drug-eluting stents and bare metal stents.

Dr Kadem Al-Lamee, CEO at Arterius Limited will lead the commercial exploitation of the product and dissemination of the project technical results.

Dr Kadem Al-Lamee said: "Biodegradable stent technology is still in the early stages however this technology has the potential to revolutionise the stent industry and improve treatment outcomes for patients with coronary and peripheral vascular disease. In conjunction with a consortium consisting of European universities and industry, Arterius' business strategy will to build a market leading portfolio of products, required for use in the next generation of drug eluting fully biodegradable stents".

Arterius' team will play a major role in collaborating with the following consortium members to achieve the technical and commercial objectives of this exciting project:

Arterius Limited, United Kingdom

The University of Westminster LBG, United Kingdom, (Scientific Coordinator is Dr. Ipsita Roy)

Ceram Limited, United Kingdom, ( Project Coordinator is Dr. Xiang Zhang)

Vornia Limited, Ireland

Spintec Engineering GmbH, Germany

Politecnico di Torino, Italy

University of Southampton, United Kingdom

Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany

Fundación TEKNIKER, Spain

Fraunhofer Institute for Production Technology IPA, Germany

University of Cambridge (The Chancellor, Masters and Scholars of the University), United Kingdom

University Clinic Bergmannsheil – Hospital of the Ruhr-University Bochum, Germany

Life and Device SRL, Italy

EURESCOM-European Institute for Research and Strategic Studies in Telecommunications GmbH, Germany

**For further information, please contact:** Dr Kadem Al-Lamee, CEO

Email: [info@arterius.co.uk](mailto:info@arterius.co.uk)

Telephone: +44 (0) 1274 23687

[www.arterius.co.uk](http://www.arterius.co.uk)

**About Arterius**

Arterius is a medical device company founded in 2010 at the Bradford Bio-Incubator, Bradford University, Yorkshire, UK to exploit opportunities in the multi-billion dollar coronary stent market. The founding directors have a long period of experience in the medical device sector in general and in the cardiovascular devices field in particular. The Company plans to develop and introduce a range of biodegradable drug eluting coronary stents. The unique properties of the Arterius polymeric stents are the high radial strength and thinner wall stent struts (<150 micron). Once these stents have produced vessel remodelling and have been encapsulated within the vessel wall, they biodegrade after a period of 12 to 24 months. The development of fully biodegradable stents that perform the necessary function of remodelling the arterial flow area and then disappear, could make a radical contribution to the priority of tackling a disease that is one of the greatest contributors to mortality in Europe and worldwide.